UNSPSC 51263144: Alprenolol benzoate

This classification denotes a beta-adrenergic blocking agent C15H23NO2.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T3H696761C, chemically known as benzoic acid, compd. with 1-((1-methylethyl)amino)-3-(2-(2-propenyl)phenoxy)-2-propanol (1:1), but more generally known as alprenolol benzoate, which bears US NIH Compound Identifier 9951320. European Medicines Agency schedules Alprenolol benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00377MIG.

Most nations, for tariff and trade purposes, schedule alprenolol benzoate under HS 29221980 and SITC 51461. As of Q4 2014, ALPRENOLOL BENZOATE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCCCC1CC=C)O.C1CCC(CC1)C(=O)O.

UNSPSC 51263144 Alprenolol benzoate is a Commodity code that in practice captures procurement of pharmaceutical products and related health-system goods, though recent state and local activity under this specific code shows minimal alignment with the nominal pharmaceutical ingredient. The Seminole County, Florida procurement (IFB 60459723LAS, posted June 30, 2026, due July 26, 2023) solicited naloxone and safe drug deactivation systems—opioid-overdose response and controlled-substance disposal equipment—rather than alprenolol benzoate specifically. The Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription fulfillment and pharmacy benefit management capabilities for a broader therapeutic initiative, again not targeting this specific pharmaceutical compound. The issuing bodies include county health departments and state health agencies pursuing community health and pharmacy benefit programs; neither recent opportunity identifies set-aside designations or disadvantaged-enterprise restrictions.

Activity concentrates in Florida and Texas, with no additional recent opportunities in the source supporting broader geographic characterization. The Seminole County IFB represents the most concrete recent procurement under the code, calling for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year term with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and all shipping included in vendor pricing. The Texas RFI functions as preliminary market intelligence rather than a formal competitive solicitation, designed to inform future state procurement strategy for direct pharmacy manufacturer relationships. Vendors responding to Seminole County must meet drug-free workplace certification, E-Verify compliance, and specified insurance requirements; the contract may be funded through FEMA, introducing federal environmental compliance obligations. The code shows limited recent activity and poor alignment between the UNSPSC taxonomy label and the health-system goods and pharmacy-program services actually being procured.